Description
Elromo 25 mg contains Eltrombopag, a thrombopoietin receptor (TPO-R) agonist that stimulates the bone marrow to produce more platelets. It is commonly prescribed in hematology for patients with low platelet counts due to immune or bone marrow-related conditions.
🔬 Mechanism of Action
Eltrombopag binds to and activates the thrombopoietin receptor on hematopoietic stem and progenitor cells in the bone marrow. As a result:
- Megakaryocyte production increases
- Platelet counts rise
- Risk of bleeding complications decreases
💊 Indications of Elromo 25 mg
Elromo 25 mg is indicated for:
- Chronic Immune Thrombocytopenia (ITP) in patients with inadequate response to corticosteroids, immunoglobulins, or splenectomy
- Severe Aplastic Anemia (SAA) in patients with insufficient response to immunosuppressive therapy
- Thrombocytopenia in Chronic Hepatitis C to allow initiation and continuation of antiviral therapy
📌 Key Features of Elromo 25 mg
- Strength: 25 mg
- Dosage Form: Oral tablet Elromo 25 mg
- Therapeutic Class: Thrombopoietin Receptor Agonist
- Administration: Taken once daily on an empty stomach (at least 1 hour before or 2 hours after meals)
- Monitoring: Regular platelet counts and liver function tests required
⚕️ Benefits of Eltrombopag
- Effectively increases platelet levels
- Reduces bleeding risk
- Oral therapy for convenient dosing
- May reduce need for platelet transfusions
⚠️ Precautions
- Risk of liver function abnormalities
- Potential risk of thrombosis if platelet counts rise excessively
- Dose adjustments based on platelet response
- Avoid use with certain supplements containing polyvalent cations near dosing time
- Use strictly under hematologist supervision
Elromo 25 mg (Eltrombopag Tablets) provides a reliable treatment option for managing chronic thrombocytopenia and related conditions, supporting improved platelet counts and patient outcomes when administered under specialized medical care.
